Royalty Pharma plc (RPRX) Stock

Royalty Pharma plc (RPRX) is a Healthcare stock trading at $52.98 (as of 2026-06-18), with a market capitalization of $31.05B and a trailing P/E of 29.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Royalty Pharma plc buys biopharmaceutical royalty interests and provides funding for biopharmaceutical innovation. It identifies, evaluates, and acquires royalties tied to marketed therapies and development-stage product candidates, working with entities such as academic institutions, research hospitals, and biopharma companies in the United States.

Valuation — source: SEC EDGAR (first-party)
Price$52.98
Market Cap$31.05B
P/E Ratio29.3
EV / EBITDA24.7
Price / Book3.12
Price / Sales12.72
DCF Value (model)$61.55
DCF Upside vs Price16.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.38B
Net Margin32.4%
Return on Equity8.3%
Debt / Equity0.90
Current Ratio2.66
Revenue Growth (YoY)11.0%
EPS Growth (YoY)21.8%
Financial Health — source: SEC EDGAR
Altman Z-Score2.42 (grey)
Valuation vs Sector & Industry
Stock P/E29.3
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector40.0%
vs Industry70.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMORGAN STANLEY ($2.09B)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPablo Legorreta
Employees75
CountryUS
IPO Date2020-06-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Insmed Incorporated (INSM)
  • Roivant Sciences Ltd. (ROIV)
  • Revolution Medicines, Inc. (RVMD)
  • BridgeBio Pharma, Inc. (BBIO)
  • Summit Therapeutics Inc. (SMMT)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Moderna, Inc. (MRNA)
RPRX earnings history · RPRX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.